Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis

Hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory syndrome driven by overactive T cells and macrophages that abundantly secrete numerous pro-inflammatory cytokines, including interferon (IFN)-gamma, interleukin (IL)-1-beta, IL-2, IL-6, IL-10, IL-18, and tumor necrosis factor (TNF)...

Full description

Bibliographic Details
Main Authors: Camille Keenan, Kim E. Nichols, Sabrin Albeituni
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
Hemophagocytic lymphohistiocytosis
ruxolitinib
jak-stat
inflammation
cytokine storm
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.614704/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.614704/full

Similar Items